Uruguay marijuana draws pharmaceuticals' interest: report

Foreign pharmaceutical companies have expressed interest in buying marijuana for medical uses from Uruguay, which last month became the world's first country to legalize the cultivation and sale of the drug, local media reported Monday.

The newspaper El Observador said the National Drug Board has been in contact with pharmaceutical laboratories from Israel and Chile, while Canadian businesses have contacted Uruguayan politicians and organizations to present proposals for buying cannabis.

"It is true they have consulted us to set up in Uruguay, which is a great challenge," presidential aide Diego Canepa told the newspaper.

Uruguay became the first country to legalize the cultivation, distribution and sale of marijuana December 24 when President Jose Mujica signed a law creating a government-regulated marketplace for the .

His government is currently drawing up specific rules and regulations that will apply.

The National Drug Board says it expects cannabis to go to market beginning in September.

"While it was not an objective of the law, Uruguay is becoming a biotechnology pole. It's a highly competitive area, but one that is rapidly developing," Canepa said.

"For some time, medicinal was only thought of as an analgesic, but now they are studying whether some derivatives can be used in medications," he said.

add to favorites email to friend print save as pdf

Related Stories

New York may allow medical marijuana use: report

Jan 05, 2014

New York is planning to loosen its marijuana laws to allow limited use of the drug by people suffering serious illness, the New York Times reported Saturday, citing state officials.

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

11 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments